GENTEL BIOSCIENCES INC

MADISON, WI · CIK 0001392432 · Biotech · Acquired

SLAMF6-targeted immunotherapeutics for immune cell modulation

gentelbio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$2.7M
1 Form D · Dec 2008
214 months since last filing
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$2,742,739
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2523NeXtGen Biologics, INC—$2.9M
2524ASSAYQUANT TECHNOLOGIES, INC.—$9.6M
2525Sonata Biosciences Inc——
2526GENTEL BIOSCIENCES INC—$2.7M
2527Insilico Medicine, Inc.—$20M
2528Nuvectis Pharma, Inc.—$16M
2529ImmuneBridge Inc.—$16M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Robert De BruinDirector
  • Randy DurnellExecutive Officer
  • Kenneth JohnsonDirector
  • Chris Kendrick-ParkerDirector
  • Larry LiozzoDirector
  • Tore RasmussenDirector
  • Lloyd SmithDirector
  • Alex VodenlichDirector · Executive Officer

Patents

USPTO · 0 granted of 1
  • Substrates For Multiplexed Assays And Uses Thereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.